Illumina Stock Plummets: The GRAIL Fail

Illumina stock $ILMN has fallen around 50% over the past rolling year as their GRAIL acquisition screeches to a halt. European regulators may soon demand that Illumina divest GRAIL and the company has already said they're pursuing strategic alternatives. It's just another failed M&A event for Illumina which also wasn't able to make their proposed acquisition of PacBio happen. Speaking of which, Illumina's long-read technology - Infinity - has now been renamed to Complete Long-Reads (CLR) and we'll need to wait until next year to see if the life sciences community is buying it.
RESEARCH PIECES USED IN THIS VIDEO:
1. Illumina Stock Falls on GRAIL Acquisition Fail
www.nanalyze.c...
2. What’s Up With Illumina’s Acquisition of GRAIL?
www.nanalyze.c...
ABOUT US:
This video is brought to you by Nanalyze, a media and research firm founded by finance professionals with decades of experience. We share insights about #DisruptiveTechnology #stocks in a language that is future-proof and easy to understand.
Read all the Nanalyze Premium articles you'd like for free! Sign up for a 30-day trial of our monthly subscription with no strings attached: www.nanalyze.c...
DISCLAIMER: Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, along with independently researching and verifying, any information contained within our CZcams videos or on our website, whether for the purpose of making an investment or otherwise.
#biotechnology #technology #pacbio #lifesciences

[@Nanalyze]

Before you start reading the comments you need to subscribe to our channel using the below link. Violators will be persecuted.👮
czcams.com/users/nanalyze

[@matthewpozega4919]

I will continue to buy more shares when the price is near $180

[@Dementia.Pugilistica]

That’s my cut off but point and approximate cost basis also

[@Nanalyze]

Sometimes it's more effective to use a ratio as a target instead of a share price. That will take into account increasing revenue over time.

[@Dementia.Pugilistica]

@@Nanalyze that’s a good point. I used a ratio and valuation tool to plot my initial cost but should probably update it at least once a year if not quarterly!

[@cameronvincent]

My gene sequencing stock 90% pacb 10% bngo

[@Nanalyze]

We've done videos on both firms - PACB (czcams.com/video/wmvw5eTOTQo/video.html), and BNGO (czcams.com/video/LCdPaAL7eY0/video.html)

[@cameronvincent]

@@Nanalyze thx (:

[@daniuskac1527]

Joe, great analysis as usual! It looks like that the next few years won't be great for Illumina.

[@Nanalyze]

Maybe a good buying opportunity. Let's see what ends up happening with GRAIL.

[@adamhanninen8295]

Thanks again Joe! I still feel bullish on their brand long term but it really depends on what their M&A’s look like. They need to be less niche and more in every CVS. They’re cheap imo

[@Nanalyze]

We're also bullish on their business but not impressed with management's M&A execution.

[@SavvyMoneyShow]

I said grail wouldn't pass because if it would this is the issue with the watchdog at the beginning they allow companies to take the risk then when it starts to pay off and they want to go all in they say no

[@Nanalyze]

Illumina totally snubbed regulators which is never a good idea. Hard to come up with a reason why that made any sense at all.

[@SavvyMoneyShow]

@@Nanalyze also the fact The earnings for next year are far less than the Trailing 12 Months. I would not pay more than $130 for $ILMN based on its projected EPS for 2023.

[@Dementia.Pugilistica]

When you dollar cost average a position delegating 20% in 5 shots or 10% in 10 shots for example, do you do it by absolute $ or amount of shares? For example if I deploy $100 at $2/share, I have 50 shares. If it drops to $1, I can buy 100 shares with $100. Do you buy 50 shares at the half price point and do the math for any price point to get the same 50 shares or just deploy by $ amount? I suppose people might do this differing ways but I wonder how you personally set up your system. I can think of possible benefits/drawbacks for either.

[@Nanalyze]

Good question. We cover that in this piece: www.nanalyze.com/2022/01/manage-tech-stock-portfolio/

[@Dementia.Pugilistica]

@@Nanalyze thanks brotha

[@GM4ThePeople]

Nanopore ftw

[@Nanalyze]

We touched on them in this piece: czcams.com/video/pZi-Swr92RY/video.html

[@GM4ThePeople]

@@Nanalyze Thanks, boss. Illumina is still an important company: they're the Intel of sequencing. ;-)